MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Hoth Therapeutics, a clinical-stage biopharmaceutical company, has been accepted into the NVIDIA Connect Program, providing the company with access to NVIDIA’s accelerated computing and AI development resources. Hoth plans to use these tools to speed computational modeling, data processing, and target evaluation across its early-stage pipeline, which includes programs in dermatology, inflammation, and oncology. The company said the program will support both internal research and collaborations by enabling larger-scale simulations and AI-driven analysis. The connection provides Hoth Therapeutics with GPU-accelerated developer tools, SDKs and APIs as well as co-marketing for increased visibility.
More
Posted by MedCloudInsider Editors on 11/24/20250 comments
Aperture Therapeutics, a preclinical biotechnology company, has announced a new development candidate targeting CD33, a receptor implicated in dysfunctional microglial activity in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The therapy is designed to restore microglial homeostasis by modulating CD33 signaling, which research shows can reduce harmful inflammatory responses and improve debris clearance in the central nervous system. The company reports that preclinical work supports CD33 as a viable path toward slowing or modifying disease progression, and the candidate will advance into IND-enabling studies.
More
Posted by MedCloudInsider Editors on 11/24/20250 comments
Citius Oncology plans to integrate Verix AI into the commercial launch of LYMPHIR, its recently approved IL-2 receptor–directed fusion protein for adults with persistent or recurrent cutaneous T-cell lymphoma (CTCL). Verix AI will support real-world patient identification, streamline specialty distribution workflows, and provide field teams with coordinated insights for clinician engagement. Citius says the platform is intended to improve speed-to-treatment in a rare cancer where diagnosis is often delayed and access pathways can be complex.
More
Posted by MedCloudInsider Editors on 11/24/20250 comments
Rapid Nexus, a medical device company, has become the first to receive FDA clearance for an advanced wound-healing gel device designed to support early-stage tissue recovery. The device, Hemastyl, uses a proprietary formulation and applicator system intended for use in emergency medicine, surgery and outpatient wound care. According to the company, Hemastyl can quickly stop bleeding while creating an environment that promotes faster healing and reduces complication risks—key needs in trauma and chronic wound settings.
More
Posted by MedCloudInsider Editors on 11/17/20250 comments
Lunit, an AI for cancer diagnostics provider and Labcorp, an innovative laboratory service provider, have announced a strategic collaboration to expand AI-powered digital pathology research, combining Labcorp’s large-scale tissue datasets with Lunit’s AI models for slide interpretation. The partnership will focus on improving biomarker discovery, refining diagnostic accuracy and supporting translational research in oncology. Lunit’s algorithms will be applied to Labcorp’s scanned pathology slides to analyze tumor microenvironments, quantify biomarkers and identify patterns that may guide treatment selection. The companies say the work will support both early-stage research and future clinical study design.
More
Posted by MedCloudInsider Editors on 11/17/20250 comments
Leucid Bio, a biotechnology company dedicated to the development of cell therapies, has shared an update from its ongoing Phase I/IIa AERIAL clinical trial evaluating LEU011, a Lateral CAR-T therapy targeting NKG2D ligands in advanced solid tumors. Interim results show sustained partial responses and evidence of immune persistence in patients with recurrent or metastatic head and neck squamous cell carcinoma. The treatment demonstrated a manageable safety profile with no new dose-limiting toxicities.
More
Posted by MedCloudInsider Editors on 11/10/20250 comments
Co-Diagnostics (Co-Dx), a molecular diagnosis company, announced plans to integrate its proprietary artificial intelligence algorithms into the Co-Dx Primer AI Platform, designed to accelerate PCR diagnostics. The AI component will analyze genomic data to identify optimal primer and probe sequences, reducing design time and enhancing specificity. The integration aims to support diagnostic applications in infectious diseases, oncology and other molecular testing markets.
More
Posted by MedCloudInsider Editors on 11/04/20250 comments
Bio-Techne, a global provider of life science tools and diagnostic products along with Nucleai, have announced an AI-powered spatial biology workflow designed to accelerate predictive biomarker discovery in melanoma research. The integrated solution uses AI and biotechnology for effective treatment options personalized to the patient's needs. Early results indicate improved accuracy in identifying biomarkers linked to patient response to immunotherapy.
More
Posted by MedCloudInsider Editors on 11/04/20250 comments
AIxMed dedicated to transforming cancer diagnosis and monitoring, together with PathNet, a digital pathology laboratory, has formed a strategic partnership to deploy an AI-powered urine cytology workflow designed to enhance early detection of bladder cancer. The system integrates AIxMed’s AIxURO™ technology with PathNet’s digital pathology network, allowing for automated cytology slide review and classification. The collaboration aims to reduce diagnostic variability, improve turnaround times and support hospitals transitioning from manual to AI-augmented pathology.
More
Posted by MedCloudInsider Editors on 11/04/20250 comments
Labviva, a leading AI-powered source-to-pay provider for life sciences, has launched its Smart Suppliers of the Future program to accelerate digital transformation in life sciences procurement. The initiative enables suppliers to digitalize their offerings and expand their reach through Labviva's supplier network. The move expands Labviva’s marketplace to over 15 million products from 18,000 manufacturers, representing 90 percent of life sciences suppliers across the U.S. and Europe.
More
Posted by MedCloudInsider Editors on 10/27/20250 comments
Harvard Health Publishing (HHP), part of Harvard Medical School, has licensed its library of consumer health content to Microsoft to train Copilot, the company’s AI assistant. The data includes articles on disease prevention, nutrition and wellness, all reviewed by Harvard scientists and researchers. The goal is to enhance Copilot’s accuracy when responding to healthcare-related questions. Microsoft confirmed that it paid for the license.
More
Posted by MedCloudInsider Editors on 10/21/20250 comments
dQ&A focuses its research efforts on diabetes to produce a unique take on treatment plans. They have released a beta version of their AI Insights Platform, designed to give healthcare companies, researchers and policymakers faster access to data on the diabetes market.
Posted by MedCloudInsider Editors on 10/17/20250 comments